Iparomlimab and Tuvonralimab (QL1706)

DRUG9 trials

Sponsors

Qilu Pharmaceutical Co., Ltd., Qilu Hospital of Shandong University, Tongji Hospital, Fudan University, Beijing Friendship Hospital

Conditions

Advanced Gastric CancerEndometrial CancerGastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction AdenocarcinomaGastroesophageal Junction CancerHER2 NegativeHormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

RecruitingNCT06932068

Qilu Hospital of Shandong UniversityHER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Start: 2025-03-26End: 2027-10-31Target: 77Updated: 2025-04-17

Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Not yet recruitingNCT06954116

Tongji HospitalResectable Hepatocellular Carcinoma With High Risk of Recurrence

Start: 2025-08-01End: 2029-04-01Target: 26Updated: 2025-06-13

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Not yet recruitingNCT07117877

Fudan UniversityOvarian Cancer (OvCa), Platinum Refractory Epithelial Ovarian Cancer, Platinum Resistant Ovarian Cancer

Start: 2025-09-15End: 2027-08-31Target: 33Updated: 2025-08-28

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

RecruitingNCT07315854

Beijing Friendship HospitalAdvanced Gastric Cancer, Gastric Cancer (GC), Gastroesophageal Junction Cancer +1

Start: 2025-11-04End: 2029-12-31Target: 32Updated: 2026-01-06

Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

Not yet recruitingNCT07369986

Women's Hospital School Of Medicine Zhejiang UniversityEndometrial Cancer, Immunotherapy, Mismatch Repair Deficiency

Start: 2026-03-01End: 2028-12-31Target: 30Updated: 2026-01-27

Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Not yet recruitingNCT07396324

RenJi HospitalHormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Start: 2026-03-01End: 2031-12-01Target: 55Updated: 2026-02-09

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

Not yet recruitingNCT07502014

Huazhong University of Science and TechnologymCRC, Metastatic Colorectal Cancer (CRC)

Start: 2026-05-01End: 2029-12-31Target: 60Updated: 2026-03-30

Phase 3

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Not yet recruitingNCT06789796

Qilu Pharmaceutical Co., Ltd.Small-cell Lung Cancer

Start: 2025-02-28End: 2030-03-31Target: 636Updated: 2025-02-11

Phase 4

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruitingNCT07502027

Huazhong University of Science and TechnologyGastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma

Start: 2026-06-01End: 2029-06-30Target: 55Updated: 2026-03-30